Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings Inc. is poised for growth, as the company's PSMA PET imaging product, POSLUMA, is projected to capture a higher share of the market, increasing to high single digits in revenue and unit share by the first quarter of 2025, up from mid-single digits. The introduction of an enhanced Pylarify formulary, which raises the batch size by approximately 50% and includes three years of TPT eligibility, is expected to revitalize growth in Pylarify as early as the fourth quarter of 2026. Additionally, the potential for increased margins and growth from Lantheus's non-Pylarify segments could drive significant earnings per share improvements in 2026 and 2027, surpassing current expectations.

Lantheus Holdings Inc is experiencing a concerning decline in its growth profile, with its two-year growth forecast now trailing behind that of its profitable SMID MedTech peers. The company's Pylarify revenue is reported at $260 million, reflecting an 8% year-over-year decline and falling approximately $14 million short of consensus expectations, highlighting significant underperformance. Additionally, Lantheus is facing challenges with lower-than-expected unit growth of only 2% year-over-year and a substantial 10% price headwind in the quarter, further contributing to the negative outlook.